Fig. 7: FOXP3 inhibitor, epirubicin, inhibited the proliferation of GBM cell and induced ferroptosis.

A RT-qPCR were performed to detect the effects of epirubicin on U87 and LN229 cell the expression level of linc00857, miR-1290 and GPX4. B CCK-8 assays were performed to detect the effects of epirubicin on U87 and LN229 cell proliferation. C Colony formation assays were performed to detect the effects of epirubicin on U87 and LN229 cell colony formation. D The ROS levels in cells were detected in U87 and LN229 cells after treatment with epirubicin. E–H The GSH, MDA, iron, and GPXs activity levels were detected in U87 and LN229 cells after treatment with epirubicin. I, J Subcutaneous tumor formation assay was used to detect the proliferation of U87 cells in vivo after treatment with epirubicin. K Tumor weight of tumor tissues derived from U87 cells treatment with epirubicin. L The in situ tumor formation model was used to detect the proliferation of U87 cells in vivo after treatment with epirubicin. M Expression of FOXP3, KI67, PCNA and GPX4 in tissues derived from U87 cells treatment with epirubicin. **P < 0.01; ***P < 0.001.